.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Astatine-211 radioimmunotherapy represents a significant milestone in targeted alpha therapy for oncological management. This innovative treatment utilizes the short-range, high-energy alpha particles of Astatine-211 to eliminate cancer cells with high precision. However, off-target accumulation in organs like the stomach and thyroid often limits its clinical utility. Researchers have recently identified a dual-protection strategy that addresses these challenges without compromising therapeutic efficacy.
The primary mechanism involves the use of sodium perchlorate (SP) alongside sodium ascorbate (SA). While sodium ascorbate prevents the denaturation of radioactive antibodies by neutralizing reactive oxygen species, it does not stop the accumulation of free Astatine in non-target tissues. Specifically, sodium perchlorate acts as a competitive inhibitor of the sodium iodide symporter (NIS). Since NIS is naturally expressed in gastric mucosal and thyroid follicular cells, its inhibition significantly reduces radioactive uptake in these areas. Consequently, this approach minimizes DNA double-strand breaks and maintains the structural integrity of the thyroid gland.
Furthermore, the study demonstrated that this combined strategy leads to significantly milder body weight loss. Additionally, the intervention did not exacerbate renal toxicity, hepatotoxicity, or transient hematotoxicity. Most importantly, the antitumor effect of the Astatine-211 radioimmunotherapy remained unaffected. Therefore, this method effectively broadens the therapeutic window, facilitating the safe clinical application of alpha-emitting radionuclides in cancer care.
Sodium perchlorate acts as a competitive inhibitor of the sodium iodide symporter (NIS), which is responsible for the accumulation of Astatine-211 in the thyroid and stomach tissues.
No, the research indicates that the antitumor efficacy remains consistent even when competitive NIS inhibition is used to protect normal organs.
Sodium ascorbate is used to protect radioactive antibodies from reactive oxygen species-induced denaturation, ensuring the stability of the radioimmunotherapy agent.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. Always consult with a qualified healthcare provider for diagnosis and treatment. Refer to the latest local and national guidelines for clinical practice.
References
Takashima H et al. Attenuated Toxicity and Antitoxic Mechanism via Sodium Iodide Symporter Inhibition-Based Tumor-Selective Delivery in Astatine-211 Radioimmunotherapy. Mol Pharm. 2026 Mar 01. doi: 10.1021/acs.molpharmaceut.5c01438. PMID: 41764644.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A study demonstrates that NIS inhibition with sodium perchlorate significantly reduces thyroid and stomach toxicity in Astatine-211 radioimmunotherapy....
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
